Haemonetics Co. (NYSE:HAE) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lowered its position in shares of Haemonetics Co. (NYSE:HAE) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 271,082 shares of the medical instruments supplier’s stock after selling 7,804 shares during the period. Victory Capital Management Inc. owned 0.54% of Haemonetics worth $21,166,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust lifted its holdings in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 240 shares during the last quarter. KBC Group NV lifted its stake in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 712 shares during the last quarter. iSAM Funds UK Ltd acquired a new position in Haemonetics in the third quarter valued at approximately $204,000. Versor Investments LP increased its stake in Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after purchasing an additional 300 shares during the last quarter. Finally, Verdence Capital Advisors LLC purchased a new position in Haemonetics in the third quarter valued at approximately $302,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on HAE shares. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. JMP Securities cut their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. JPMorgan Chase & Co. started coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Finally, Raymond James restated a “strong-buy” rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Price Performance

HAE stock opened at $68.51 on Wednesday. The stock’s 50 day moving average price is $69.40 and its 200 day moving average price is $75.63. The firm has a market cap of $3.44 billion, a P/E ratio of 26.97, a PEG ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, sell-side analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.